Androgen receptor modulation optimized for response: Splice variant (ARMOR3-SV)–Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant.

Authors

Mary-Ellen Taplin

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Mary-Ellen Taplin , Emmanuel S. Antonarakis , Daniel T. Dransfield , Karen J. Ferrante , Johann Sebastian De Bono

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant (ARMOR3-SV).

First Author: Emmanuel S. Antonarakis

insert_chart_outlined

Poster

2015 Genitourinary Cancers Symposium

bookmark_border

Androgen Receptor Modulation Optimized for Response in Splice Variant (ARMOR3-SV): Randomized, open-label, multicenter, controlled study of galeterone versus enzalutamide (enz) in men expressing AR-V7 splice variant (SV), metastatic castrate resistant prostate cancer (mCRPC).

First Author: Jennifer Roberts

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.

First Author: Siyuan S Guo

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.

First Author: Syed A. Hussain